KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Preferred Stock Liabilities (2018 - 2019)

Castle Biosciences (CSTL) has disclosed Preferred Stock Liabilities for 2 consecutive years, with $45.1 million as the latest value for Q2 2019.

  • Quarterly Preferred Stock Liabilities rose 2905.19% to $45.1 million in Q2 2019 from the year-ago period, while the trailing twelve-month figure was $45.1 million through Jun 2019, up 2905.19% year-over-year, with the annual reading at $2.9 million for FY2018, N/A changed from the prior year.
  • Preferred Stock Liabilities hit $45.1 million in Q2 2019 for Castle Biosciences, up from $1.5 million in the prior quarter.
  • In the past five years, Preferred Stock Liabilities ranged from a high of $45.1 million in Q2 2019 to a low of $1.5 million in Q2 2018.